UBS Warburg to Webcast The Medicines Company's Corporate Presentation
PARSIPPANY, N.J.--(BW HealthWire)--June 4, 2002--The Medicines Company (NASDAQ: MDCO - News) announced today that its corporate presentation at the UBS Warburg Specialty Pharmaceuticals Conference will be webcast live on Wednesday, June 5, 2002 at 10:30am ET. The webcast may be viewed at The Medicines Company's homepage, www.themedicinescompany.com and will be archived for 30 days.
Dave Stack, President and CEO and Steven Koehler, CFO will present an overview of the company at 10:30am on Wednesday, June 5, 2002 from the Grand Hyatt Hotel in New York, NY.
The Medicines Company was founded in 1996 to acquire, develop and commercialize selected pharmaceutical products in late stages of development and approved products. ANGIOMAX® (bivalirudin) is approved in the United States for use as an intravenous anticoagulant in combination with aspirin in patients with unstable angina undergoing coronary balloon angioplasty, and is expected to be the cornerstone product of a planned acute-care hospital franchise. The Company is also developing another intravenous agent, clevidipine, for the short-term control of high blood pressure in the hospital setting. The Company's website can be found at www.themedicinescompany.com.
This press release contains forward-looking statements that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words, "believes," "anticipates," "plans," "expects," "intends," and similar expressions are intended to identify forward-looking statements. Important factors that could cause actual results to differ materially from the expectations described in these forward-looking statements are set forth under the caption "Certain Factors that May Affect Future Results" in the Company's Annual Report on Form 10-Q filed with the Securities and Exchange Commission on June 15, 2002 and incorporated herein by reference. These risk factors include risks as to the commercial success of ANGIOMAX; how long the Company will be able to operate on its existing capital resources; whether the Company's products (other than ANGIOMAX for its approved indication) will advance in the clinical trials process, the timing of such clinical trials, whether the clinical trial results will warrant continued product development, whether and when, if at all, the Company's products will receive approval from the U.S. Food and Drug Administration or equivalent regulatory agencies, and for which indications, and, if such products receive approval, whether they will be successfully marketed; whether the Company will be able to develop or acquire additional products; the Company's history of net losses; and the Company's dependence on third parties, including manufacturers, suppliers and collaborators. We do not assume any obligation to update any forward-looking statements.
--------------------------------------------------------------------------------
Contact:
The Medicines Company
Steven Koehler, 973/656-1616
Fax: 973/656-9898
Jill Sawdon, 617/225-9099
Fax: 617/225-2397 |
